Time course of changes in pyridoxal 5′-phosphate (vitamin B6 active form) and its neuroprotection in experimental ischemic damage

In Koo Hwang, Ki Yeon Yoo, Do Hoon Kim, Bong Hee Lee, Young-Guen Kwon, Moo Ho Won

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

In the present study, we investigated ischemia-induced changes of pyridoxal 5′-phosphate synthesizing enzyme and degrading enzyme and neuroprotective effects and roles of pyridoxal 5′-phosphate against ischemic damage in the gerbil hippocampal CA1 region. Pyridoxal 5′-phosphate oxidase and pyridoxal phosphate phosphatase immunoreactivities were changed in neurons up to 2 days after ischemia, while 4 days after ischemia their immunoreactivities were expressed in astrocytes. Pyridoxal 5′-phosphate oxidase immunoreactivity and its protein level were highest 12 h after ischemia, while those in pyridoxal phosphate phosphatase were highest 2 days after ischemia. Total activities of these enzymes were changed after ischemia, but specific activities of the enzymes were not altered. Treatment with pyridoxal 5′-phosphate into brains (4 μg/5 μl, i.c.v.) at 30 min before transient ischemia protected about 80% of CA1 pyramidal cells 4 days after ischemia and induced elevation of glutamic acid decarboxylase 67 immunoreactivity in the CA1 region. However, pyridoxal 5′-phosphate treatment into ischemic brains decreased GABA transaminase immunoreactivity in the CA1 region after ischemia. These results indicate that pyridoxal 5′-phosphate may be associated with the inhibitory discharge of GABA in the hippocampal CA1 neurons, and the increased level of GABA may protect hippocampal CA1 pyramidal cells from ischemic damage.

Original languageEnglish
Pages (from-to)114-125
Number of pages12
JournalExperimental Neurology
Volume206
Issue number1
DOIs
Publication statusPublished - 2007 Jul 1

Fingerprint

Vitamin B 6
Pyridoxal Phosphate
Ischemia
Pyramidal Cells
Enzymes
gamma-Aminobutyric Acid
Oxidoreductases
4-Aminobutyrate Transaminase
Hippocampal CA1 Region
Neuroprotection
Neurons
Glutamate Decarboxylase
Gerbillinae
Brain
Neuroprotective Agents
Astrocytes

All Science Journal Classification (ASJC) codes

  • Neurology
  • Developmental Neuroscience

Cite this

Hwang, In Koo ; Yoo, Ki Yeon ; Kim, Do Hoon ; Lee, Bong Hee ; Kwon, Young-Guen ; Won, Moo Ho. / Time course of changes in pyridoxal 5′-phosphate (vitamin B6 active form) and its neuroprotection in experimental ischemic damage. In: Experimental Neurology. 2007 ; Vol. 206, No. 1. pp. 114-125.
@article{fb00913d4f0741f9b5649d63027921ee,
title = "Time course of changes in pyridoxal 5′-phosphate (vitamin B6 active form) and its neuroprotection in experimental ischemic damage",
abstract = "In the present study, we investigated ischemia-induced changes of pyridoxal 5′-phosphate synthesizing enzyme and degrading enzyme and neuroprotective effects and roles of pyridoxal 5′-phosphate against ischemic damage in the gerbil hippocampal CA1 region. Pyridoxal 5′-phosphate oxidase and pyridoxal phosphate phosphatase immunoreactivities were changed in neurons up to 2 days after ischemia, while 4 days after ischemia their immunoreactivities were expressed in astrocytes. Pyridoxal 5′-phosphate oxidase immunoreactivity and its protein level were highest 12 h after ischemia, while those in pyridoxal phosphate phosphatase were highest 2 days after ischemia. Total activities of these enzymes were changed after ischemia, but specific activities of the enzymes were not altered. Treatment with pyridoxal 5′-phosphate into brains (4 μg/5 μl, i.c.v.) at 30 min before transient ischemia protected about 80{\%} of CA1 pyramidal cells 4 days after ischemia and induced elevation of glutamic acid decarboxylase 67 immunoreactivity in the CA1 region. However, pyridoxal 5′-phosphate treatment into ischemic brains decreased GABA transaminase immunoreactivity in the CA1 region after ischemia. These results indicate that pyridoxal 5′-phosphate may be associated with the inhibitory discharge of GABA in the hippocampal CA1 neurons, and the increased level of GABA may protect hippocampal CA1 pyramidal cells from ischemic damage.",
author = "Hwang, {In Koo} and Yoo, {Ki Yeon} and Kim, {Do Hoon} and Lee, {Bong Hee} and Young-Guen Kwon and Won, {Moo Ho}",
year = "2007",
month = "7",
day = "1",
doi = "10.1016/j.expneurol.2007.04.005",
language = "English",
volume = "206",
pages = "114--125",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",
number = "1",

}

Time course of changes in pyridoxal 5′-phosphate (vitamin B6 active form) and its neuroprotection in experimental ischemic damage. / Hwang, In Koo; Yoo, Ki Yeon; Kim, Do Hoon; Lee, Bong Hee; Kwon, Young-Guen; Won, Moo Ho.

In: Experimental Neurology, Vol. 206, No. 1, 01.07.2007, p. 114-125.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Time course of changes in pyridoxal 5′-phosphate (vitamin B6 active form) and its neuroprotection in experimental ischemic damage

AU - Hwang, In Koo

AU - Yoo, Ki Yeon

AU - Kim, Do Hoon

AU - Lee, Bong Hee

AU - Kwon, Young-Guen

AU - Won, Moo Ho

PY - 2007/7/1

Y1 - 2007/7/1

N2 - In the present study, we investigated ischemia-induced changes of pyridoxal 5′-phosphate synthesizing enzyme and degrading enzyme and neuroprotective effects and roles of pyridoxal 5′-phosphate against ischemic damage in the gerbil hippocampal CA1 region. Pyridoxal 5′-phosphate oxidase and pyridoxal phosphate phosphatase immunoreactivities were changed in neurons up to 2 days after ischemia, while 4 days after ischemia their immunoreactivities were expressed in astrocytes. Pyridoxal 5′-phosphate oxidase immunoreactivity and its protein level were highest 12 h after ischemia, while those in pyridoxal phosphate phosphatase were highest 2 days after ischemia. Total activities of these enzymes were changed after ischemia, but specific activities of the enzymes were not altered. Treatment with pyridoxal 5′-phosphate into brains (4 μg/5 μl, i.c.v.) at 30 min before transient ischemia protected about 80% of CA1 pyramidal cells 4 days after ischemia and induced elevation of glutamic acid decarboxylase 67 immunoreactivity in the CA1 region. However, pyridoxal 5′-phosphate treatment into ischemic brains decreased GABA transaminase immunoreactivity in the CA1 region after ischemia. These results indicate that pyridoxal 5′-phosphate may be associated with the inhibitory discharge of GABA in the hippocampal CA1 neurons, and the increased level of GABA may protect hippocampal CA1 pyramidal cells from ischemic damage.

AB - In the present study, we investigated ischemia-induced changes of pyridoxal 5′-phosphate synthesizing enzyme and degrading enzyme and neuroprotective effects and roles of pyridoxal 5′-phosphate against ischemic damage in the gerbil hippocampal CA1 region. Pyridoxal 5′-phosphate oxidase and pyridoxal phosphate phosphatase immunoreactivities were changed in neurons up to 2 days after ischemia, while 4 days after ischemia their immunoreactivities were expressed in astrocytes. Pyridoxal 5′-phosphate oxidase immunoreactivity and its protein level were highest 12 h after ischemia, while those in pyridoxal phosphate phosphatase were highest 2 days after ischemia. Total activities of these enzymes were changed after ischemia, but specific activities of the enzymes were not altered. Treatment with pyridoxal 5′-phosphate into brains (4 μg/5 μl, i.c.v.) at 30 min before transient ischemia protected about 80% of CA1 pyramidal cells 4 days after ischemia and induced elevation of glutamic acid decarboxylase 67 immunoreactivity in the CA1 region. However, pyridoxal 5′-phosphate treatment into ischemic brains decreased GABA transaminase immunoreactivity in the CA1 region after ischemia. These results indicate that pyridoxal 5′-phosphate may be associated with the inhibitory discharge of GABA in the hippocampal CA1 neurons, and the increased level of GABA may protect hippocampal CA1 pyramidal cells from ischemic damage.

UR - http://www.scopus.com/inward/record.url?scp=34250690463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250690463&partnerID=8YFLogxK

U2 - 10.1016/j.expneurol.2007.04.005

DO - 10.1016/j.expneurol.2007.04.005

M3 - Article

C2 - 17531224

AN - SCOPUS:34250690463

VL - 206

SP - 114

EP - 125

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

IS - 1

ER -